Metagenomi (MGX) Expected to Release Earnings on Tuesday

Metagenomi (NASDAQ:MGX) will likely be posting its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.5531) per share and revenue of $3.01 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Metagenomi (NASDAQ:MGX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The company had revenue of $1.25 million for the quarter, compared to analyst estimates of $5.90 million. Metagenomi had a negative return on equity of 51.23% and a negative net margin of 384.61%. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Metagenomi Price Performance

MGX traded up $0.01 during trading on Tuesday, hitting $1.23. The company had a trading volume of 26,696 shares, compared to its average volume of 209,142. The company has a market cap of $46.12 million, a PE ratio of -0.53 and a beta of 0.66. The business has a 50-day moving average of $1.25 and a 200-day moving average of $1.39. Metagenomi has a 1-year low of $1.13 and a 1-year high of $3.95.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company dropped their target price on shares of Metagenomi from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings cut shares of Metagenomi from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 23rd. Wall Street Zen upgraded Metagenomi from a “strong sell” rating to a “sell” rating in a research note on Monday, July 20th. Finally, Chardan Capital began coverage on Metagenomi in a report on Tuesday, July 7th. They issued a “buy” rating and a $5.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Metagenomi presently has an average rating of “Moderate Buy” and an average target price of $7.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC raised its position in shares of Metagenomi by 276.3% during the 4th quarter. Renaissance Technologies LLC now owns 628,400 shares of the company’s stock worth $1,018,000 after purchasing an additional 461,400 shares during the period. Jane Street Group LLC boosted its position in Metagenomi by 341.6% during the 4th quarter. Jane Street Group LLC now owns 433,859 shares of the company’s stock valued at $703,000 after purchasing an additional 335,604 shares during the period. Norges Bank bought a new position in Metagenomi during the 2nd quarter worth $373,000. Bridgeway Capital Management LLC grew its stake in Metagenomi by 102.1% during the 4th quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock worth $641,000 after buying an additional 200,000 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in Metagenomi by 1,394.4% in the third quarter. Two Sigma Investments LP now owns 207,528 shares of the company’s stock worth $492,000 after buying an additional 193,641 shares during the period.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.